What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

XBiotech

Directions Website

XBiotech is a fully integrated biopharmaceutical that uses proprietary technology to create True Human™ monoclonal antibody medicines.

True Human™ antibodies harness natural immunity and allow us to share the best of natural immunity for all. At XBiotech we are rethinking the way medicines are discovered and commercialized—from pioneering ways to create safer drugs that harness our natural immunity to disease, to developing technology that enables rapid transition from discovery to large-scale manufacturing.

10/23/2026

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-announces-election-sushma-shivaswamy-and-jan-paul

$XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metas...$

10/19/2026

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-announces-positive-phase-ii-final-efficacy-results?fbclid=IwY2xjawVC9z1leHRuA2FlbQIxMQBwZG9mAXNydGMGYXBwX2lkEDIyMjAzOTE3ODgyMDA4OTIAAR5jUcQMQkgnsKkQPl6qxubJPN6TI-r__Itz9a15s-n_anIUuaOMMlQvwu5x6A_aem__dppchvCqX3K_QPncFzWkA

08/19/2026

XBiotech Scientists Demonstrate Therapeutic Potential of IL-1α Blockade in Pulmonary Melanoma

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

06/15/2026

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug

05/01/2026

From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

03/06/2026

XBiotech Awarded Three U.S. Patents Protecting Next-Generation True Human™ Antibodies Targeting Interleukin-1 Alpha

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

02/04/2026

https://www.xbiotech.com/news/advancing-infectious-disease-innovation

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

12/23/2024

XBiotech Pauses Rheumatology program
https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-pauses-rheumatology-program

08/23/2024

XBiotech We Believe.

XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technolo...

06/18/2024

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind,

Address

5217 Winnebago Lane
Austin, TX
78744

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

http://www.xbiotech.com/

Alerts

Be the first to know and let us send you an email when XBiotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.